Key Questions RAS Can Help You Answer

  • What will the future biosimilar market look like?

  • What does the clinical landscape of biosimilar competition look like?

  • How to keep pace with the evolving biosimilar policies and regulations?

  • How will litigations and judgements impact biosimilar market?

  • What are the key drivers for biosimilar adoption? How will switch-study benefit adoption?

  • Will the clinical data requirements change overtime? Will analytical data play a bigger role?

  • How to differentiate in the biosimilar market?

  • How to create & manage biosimilar portfolio for sustenance?

Featured Insights

May 14, 2018 / Biosimilars, Featured Insights

Biosimilar Clinical Development – A Strategic Lever?

The presentation gives some key insights on the emerging biosimilars developer landscape with focus on US, EU, China, Japan, South Korea, MENA and Indian markets. Furthermore, it provides a detailed analysis on Clinical differentiation of players for major products (Bevacizumab, Trastuzumab, Adalimumab, Rituximab, Infliximab and etanercept).
Read More
July 18, 2017 / Biosimilars, Featured Insights

Indian Biosimilar – Slow but Steady?

The white paper attempts to infer the biosimilar play of India-based biosimilar developers. It explores plausible scenarios for Indian developers entering the lucrative US and EU biosimilar market based on the current situation analysis of major biosimilar developers.
Read More
July 18, 2017 / Biosimilars, Featured Insights, Oncology

Oncology Biosimilar Competitive Dynamics

This paper attempts to present situation analysis of the current marketplace of Oncology biosimilars specially with respect to the industry’s micro-environment. The research and analysis herein, intends to identify positive forces and interactions that are shaping an attractive biosimilar industry in both US and EU markets.
Read More

What would you like to know?